肺癌患者异常糖链糖蛋白与传统肿瘤标志物的相关性分析
|
摘要
目的通过回顾性分析肺癌患者异常糖链糖蛋白(TAP)水平以及传统肿瘤标志物癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)、糖类抗原125(CA125)、神经元特异性烯醇化酶(NSE)和细胞角蛋白19片段(CYFRA21-1)水平,探讨肺癌患者TAP与传统肿瘤标志物之间的相互关系。方法分别采用凝聚素亲和法及电化学发光免疫分析法检测我院呼吸内科经治的181例肺癌患者TAP和5种血清学肿瘤标志物的水平,对所得TAP与5种血清学肿瘤标志物的数据进行spearman相关性检验分析。结果肺癌患者TAP与CEA呈正相关(P=0.016),而与SCC、CA125、NSE及CYFRA21-1之间没有相关性(P值均>0.05);亚组分析,腺癌、鳞癌患者的TAP与CEA均呈正相关(P值分别为0.021,0.044),腺癌、鳞癌、小细胞癌及未分类癌患者的TAP与CA125均呈正相关(P值分别0.046,0.007,0.001,0.006),而这四类癌的TAP与SCC、NSE和CYFRA21-1之间没有明显相关性(P值均>0.05)。结论肺癌患者TAP值是CEA、CA125等多种肿瘤异常蛋白水平的综合体现,尤其在肺腺癌患者中与传统肿瘤标志物具有较好的正相关性。
Objective The levels of tumor abnormal protein( TAP) and tumor markers( CEA,SCC,CA125,NSE and CYFRA21-1) were studied in patients with lung cancer,to explore their correlation between TAP and tumor markers in lung cancer. Methods 181 cases of patients with lung cancer were recruited in Department of Respiratory Medicine Tang Du Hospital. TAP was measured by coacervation method. And their CEA,SCC, CA125, NSE and CYFRA21-1 were measured by Electro-Chemiluminescence immunoassay( ECLI). Then the relations between TAP and Tumor Markers were analyzed by spearman correlation test.Results There was a positive correlation between TAP and CEA in lung cancer patients( P = 0.016),but no correlation with SCC,CA125,NSE and CYFRA21-1( P>0.05). And subgroup analysis,there was a positive correlation between TAP and CEA in patients with adenocarcinoma and squamous cell carcinoma( P = 0.021,0.044,respectively), a positive correlation between TAP and CA125 in patients with adenocarcinoma,squamous cell carcinoma,small cell carcinoma,and unclassified cancer( P values were 0.046,0.007,0.001,0. 006, respectively). However, there was no significant correlation between TAP and SCC, NSE and CYFRA21-1 in the four types of lung cancer( P > 0. 05). Conclusion The TAP value is a comprehensive manifestation of a variety of abnormal tumor proteins,such as CEA and CA125,in lung cancer patients.Especially,there was a good positive correlation between TAP and traditional TM in patients with lung adenocarcinoma.
Objective The levels of tumor abnormal protein( TAP) and tumor markers( CEA,SCC,CA125,NSE and CYFRA21-1) were studied in patients with lung cancer,to explore their correlation between TAP and tumor markers in lung cancer. Methods 181 cases of patients with lung cancer were recruited in Department of Respiratory Medicine Tang Du Hospital. TAP was measured by coacervation method. And their CEA,SCC, CA125, NSE and CYFRA21-1 were measured by Electro-Chemiluminescence immunoassay( ECLI). Then the relations between TAP and Tumor Markers were analyzed by spearman correlation test.Results There was a positive correlation between TAP and CEA in lung cancer patients( P = 0.016),but no correlation with SCC,CA125,NSE and CYFRA21-1( P>0.05). And subgroup analysis,there was a positive correlation between TAP and CEA in patients with adenocarcinoma and squamous cell carcinoma( P = 0.021,0.044,respectively), a positive correlation between TAP and CA125 in patients with adenocarcinoma,squamous cell carcinoma,small cell carcinoma,and unclassified cancer( P values were 0.046,0.007,0.001,0. 006, respectively). However, there was no significant correlation between TAP and SCC, NSE and CYFRA21-1 in the four types of lung cancer( P > 0. 05). Conclusion The TAP value is a comprehensive manifestation of a variety of abnormal tumor proteins,such as CEA and CA125,in lung cancer patients.Especially,there was a good positive correlation between TAP and traditional TM in patients with lung adenocarcinoma.
引文
1钱桂生.肺癌不同病理类型发病率的变化情况及原因[J/CD].中华肺部疾病杂志(电子版),2011,4(1):1-6.
2 Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CACancer J Clin,2010,60(5):277-300.
3 Smith RA,Cokkinides V,Brawley OW.Cancer screening in the United States,2009:a review of current American Cancer Society guidelines and issues in cancer screening[J].CA Cancer J Clin,2009,59(1):27-41.
4邴振,卢愿,孙立荣,等.异常糖链糖蛋白在肿瘤发生发展中的作用及检测进展[J].齐鲁医学杂志,2015,30(2):245-246,252.
5 Zhang L,Guo X,Min Y,et al.Tumor abnormal protein(TAP)examination contributes to primary diagnosis of bladder cancer[J].Int J Clin Exp Med,2015,8(10):18528-18532.
6刘丽燕,陈晓丹,杨明夏,等.外周血异常糖链糖蛋白检测对非小细胞肺癌患者治疗监测的意义[J].现代检验医学杂志,2017,32(1):103-105.
7祁洁,邹士涛,李晓庆.血清癌胚抗原、糖链抗原153与异常糖链糖蛋白在乳腺癌诊断中的应用[J].临床与病理杂志,2017,37(6):1211-1215.
8金韩,展红光,崔熙.肿瘤异常蛋白检测系统对消化系统肿瘤检测效力的评价[J].现代医学,2006,34(4):270-271.
9何萍,徐昌维,单喜花,等.肿瘤异常蛋白对肺癌患者近期疗效的意义[J].河北中医,2014,36(12):1915-1916.
10邱志远,陶曙,雷珍,等.肿瘤异常蛋白在胃肠肿瘤中的临床价值[J].癌症进展,2016,14(4):340-342.
11王义霞,胡涛,徐尊花,等.肿瘤异常蛋白检测系统在早期妇科恶性肿瘤筛查中的应用价值[J].中国实验诊断学,2016,20(5):745-747.
12史英,柳志宝,高敬华,等.肿瘤异常蛋白对消化道恶性肿瘤的表达及化疗疗效评价[J].中国综合临床,2015,31(12):1125-1127.
13黄婷婷,江倩,杜婷,等.肺癌患者肿瘤异常糖链蛋白的表达及其意义[J].实用医学杂志,2017,33(24):4149-4152.
14陈国千.糖蛋白糖链结构分析与恶性肿瘤的诊断[J].国外医学临床生物化学与检验学分册,2000,21(4):171-173.
15王彦人,罗毅,田雅军.异常糖链糖蛋白检测在肿瘤早期筛查中的应用进展[J].齐齐哈尔医学院学报,2018,39(1):79-81.
16徐阳,孙英刚,孙力勇,等.异常糖链糖蛋白检测对恶性肿瘤患者临床意义的研究现状[J].中国医药生物技术,2017,12(5):445-448.
17 Partridge EA,Le Roy C,Di Guglielmo GM,et al.Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis[J].Science,2004,306(5693):120-124.
18姜峰,杜然.TAP联合Ki-67对判断非小细胞肺癌患者预后的临床意义[J].临床与实验病理学杂志,2017,33(1):104-106.
19蒋贝兰,沙杭.肺癌血清肿瘤标志物的研究现状及进展[J].天津医药,2014,42(4):393-395.
20张红军,顾兴,刘伟,等.肿瘤标志物动态变化在肺癌疗效判断与随访中的意义[J/CD].中华肺部疾病杂志(电子版),2016,9(1):26-30.
21陈阳阳,张洁,徐国宾.晚期肺癌患者一线化疗后6种血清肿瘤标志物水平的变化及意义[J].临床检验杂志,2015,33(2):124-129.
2 Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CACancer J Clin,2010,60(5):277-300.
3 Smith RA,Cokkinides V,Brawley OW.Cancer screening in the United States,2009:a review of current American Cancer Society guidelines and issues in cancer screening[J].CA Cancer J Clin,2009,59(1):27-41.
4邴振,卢愿,孙立荣,等.异常糖链糖蛋白在肿瘤发生发展中的作用及检测进展[J].齐鲁医学杂志,2015,30(2):245-246,252.
5 Zhang L,Guo X,Min Y,et al.Tumor abnormal protein(TAP)examination contributes to primary diagnosis of bladder cancer[J].Int J Clin Exp Med,2015,8(10):18528-18532.
6刘丽燕,陈晓丹,杨明夏,等.外周血异常糖链糖蛋白检测对非小细胞肺癌患者治疗监测的意义[J].现代检验医学杂志,2017,32(1):103-105.
7祁洁,邹士涛,李晓庆.血清癌胚抗原、糖链抗原153与异常糖链糖蛋白在乳腺癌诊断中的应用[J].临床与病理杂志,2017,37(6):1211-1215.
8金韩,展红光,崔熙.肿瘤异常蛋白检测系统对消化系统肿瘤检测效力的评价[J].现代医学,2006,34(4):270-271.
9何萍,徐昌维,单喜花,等.肿瘤异常蛋白对肺癌患者近期疗效的意义[J].河北中医,2014,36(12):1915-1916.
10邱志远,陶曙,雷珍,等.肿瘤异常蛋白在胃肠肿瘤中的临床价值[J].癌症进展,2016,14(4):340-342.
11王义霞,胡涛,徐尊花,等.肿瘤异常蛋白检测系统在早期妇科恶性肿瘤筛查中的应用价值[J].中国实验诊断学,2016,20(5):745-747.
12史英,柳志宝,高敬华,等.肿瘤异常蛋白对消化道恶性肿瘤的表达及化疗疗效评价[J].中国综合临床,2015,31(12):1125-1127.
13黄婷婷,江倩,杜婷,等.肺癌患者肿瘤异常糖链蛋白的表达及其意义[J].实用医学杂志,2017,33(24):4149-4152.
14陈国千.糖蛋白糖链结构分析与恶性肿瘤的诊断[J].国外医学临床生物化学与检验学分册,2000,21(4):171-173.
15王彦人,罗毅,田雅军.异常糖链糖蛋白检测在肿瘤早期筛查中的应用进展[J].齐齐哈尔医学院学报,2018,39(1):79-81.
16徐阳,孙英刚,孙力勇,等.异常糖链糖蛋白检测对恶性肿瘤患者临床意义的研究现状[J].中国医药生物技术,2017,12(5):445-448.
17 Partridge EA,Le Roy C,Di Guglielmo GM,et al.Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis[J].Science,2004,306(5693):120-124.
18姜峰,杜然.TAP联合Ki-67对判断非小细胞肺癌患者预后的临床意义[J].临床与实验病理学杂志,2017,33(1):104-106.
19蒋贝兰,沙杭.肺癌血清肿瘤标志物的研究现状及进展[J].天津医药,2014,42(4):393-395.
20张红军,顾兴,刘伟,等.肿瘤标志物动态变化在肺癌疗效判断与随访中的意义[J/CD].中华肺部疾病杂志(电子版),2016,9(1):26-30.
21陈阳阳,张洁,徐国宾.晚期肺癌患者一线化疗后6种血清肿瘤标志物水平的变化及意义[J].临床检验杂志,2015,33(2):124-129.